Suman Kambhampati, MD
Myelodysplastic syndromes (MDS), precursors to acute myeloid leukemia (AML), are underdiagnosed, according to Suman Kambhampati, MD.
on Hematologic Malignancies, Kambhampati, co-medical director of the Blood Cancer Program at Sarah Cannon Cancer Institute, detailed available treatments for MDS and ongoing clinical trials investigating targeted treatments in myeloid malignancies.
OncLive: Please provide an overview of the treatment landscape of MDS.
The 2 main features in MDS are low blood counts and the risk of transforming into AML; those are the 2 broad areas of therapeutic focus. When it comes to low blood counts, we primarily deal with anemia, thrombocytopenia, low platelets, and risk for infections due to low neutrophil counts. MDS is categorized into low- and high-risk disease. Low-risk MDS is often characterized by low blood counts, and the focus in that category is mostly improving blood counts and giving growth factors to stimulate blood production.
... to read the full story